ENTITY Chimagen Biosciences

Chimagen Biosciences

PulseAugur coverage of Chimagen Biosciences — every cluster mentioning Chimagen Biosciences across labs, papers, and developer communities, ranked by signal.

Show in brief

Total · 30d

1 over 90d

Releases · 30d

0 over 90d

Papers · 30d

0 over 90d

TIER MIX · 90D

TOPICS

funding 1
product 1

SENTIMENT · 30D

1 day(s) with sentiment data

RECENT · PAGE 1/1 · 1 TOTAL

RESEARCH · CL_256637 · Sep 16 · 02:00

GSK licenses Chinese cancer drug for up to $750M

GSK has agreed to acquire global rights to a novel T-cell engager cancer drug from Chinese firm Chimagen Biosciences. The deal, potentially worth up to US$750 million, focuses on a treatment for multiple myeloma that ai…

GSK licenses Chinese cancer drug for up to $750M